Andreas M. Beyer Ph.D. FAHA, FCVS-APS

About Andreas M. Beyer Ph.D. FAHA, FCVS-APS

My research focuses on translational aspects of vascular pathophysiology with an emphasis on microvascular endothelial (dys)function. The mechanisms that cause disease-induced
microvascular dysfunction remain ill-defined and represent a critical gap in knowledge. My lab employs innovative approaches to understand the clinical relevance of mitochondrial stress
responses in the human microcirculation. Our ongoing research implicates changes in mitochondrial integrity as a cause of endothelial dysfunction in patients with coronary artery
disease (CAD, i.e., atherosclerosis). These findings informed a new line of investigation focused on understanding how cancer and anti-cancer therapies (CTx, including chemotherapy
and molecular therapies) damage the microcirculation and increase the risk of major adverse cardiovascular events (MACE) in cancer survivors. As part of an integrated group of
investigators, the Beyer lab is a leader among those focused on studying the human microcirculation. We apply translational approaches to define physiological and molecular
mechanisms that contribute to development and progression of cardiovascular disease (CVD). Our ground-breaking findings led to re-evaluation of how microvascular tone is regulated in
patients. My lab is well-positioned and has all necessary expertise to investigate how microvascular dysfunction contributes to the interaction between cancer and CVD. I have the
scientific curiosity, motivation, preparation, expertise and leadership experience to accomplish the objectives of this proposal.